Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ReGen Biologics’ Collagen Scaffold Goes To FDA Panel Nov. 14

This article was originally published in The Gray Sheet

Executive Summary

FDA's Orthopaedic and Rehabilitation Devices Panel will meet Nov. 14 to review an updated 510(k) submission for ReGen Biologics' Collagen Scaffold knee cartilage repair product
Advertisement

Related Content

ReGen Biologics’ Collagen Scaffold efficacy data questioned by panel
ReGen Biologics’ Collagen Scaffold efficacy data questioned by panel
Research In Brief
Research In Brief
ReGen Says Lack Of FDA Sports Med Specialists Blocks Its Knee Product
Advertisement
UsernamePublicRestriction

Register

MT026779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel